• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Erica L. Mayer, M.D. M.P.H.


  • Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C.Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101.J Clin Oncol. 2012 Nov 20;30(33):4071-6.
  • Mayer EL, Lin NU.Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab?.J Clin Oncol. 2012 Nov 1;30(31):3769-72.
  • Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ.Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Breast Cancer Res Treat. 2012 Nov;136(1):169-78.
  • Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol. 2012 Jul 20;30(21):2615-23.
  • Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, Bellmunt J, Burstein HJ, Schutz FA.Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab.J Clin Oncol. 2011 Jan 4.
  • Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A.Cardiac toxicity from systemic cancer therapy: a comprehensive review.Prog Cardiovasc Dis.;53(2):94-104. Review.
  • Mayer EL, Krop IE.Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.Clin Cancer Res. 2010 Jul 15;16(14):3526-32.
  • Mayer EL, Burstein HJ.Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.J Clin Oncol. 2008 Mar 10;26(8):1198-200.
  • Mayer EL, Carey LA, Burstein HJ.Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.Breast Cancer Res. 2007;9(5):110.
  • Mayer EL, Burstein HJ.Chemotherapy for metastatic breast cancer.Hematol Oncol Clin North Am. 2007 Apr;21(2):257-72. Review.
  • Mayer EL, Lin NU, Burstein HJ.Novel approaches to advanced breast cancer: bevacizumab and lapatinib.J Natl Compr Canc Netw. 2007 Mar;5(3):314-23. Review.